|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0031740,
umls-concept:C0205195,
umls-concept:C0242383,
umls-concept:C0332281,
umls-concept:C0387288,
umls-concept:C0600518,
umls-concept:C0796392,
umls-concept:C1135130,
umls-concept:C1517572,
umls-concept:C1656863,
umls-concept:C2603343
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2007-8-16
|
|
pubmed:abstractText |
A novel alternative for combined treatment using verteporfin photodynamic therapy (PDT) has emerged as preliminary safety and efficacy data of the intravitreal use of the anti-angiogenic bevacizumab became available. In the current study we investigate the feasibility of intravitreal bevacizumab combined with verteporfin PDT for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Photosensitizing Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Porphyrins,
http://linkedlifedata.com/resource/pubmed/chemical/VEGFA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab,
http://linkedlifedata.com/resource/pubmed/chemical/verteporfin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0721-832X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
245
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1273-80
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17333238-Aged,
pubmed-meshheading:17333238-Aged, 80 and over,
pubmed-meshheading:17333238-Angiogenesis Inhibitors,
pubmed-meshheading:17333238-Antibodies, Monoclonal,
pubmed-meshheading:17333238-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17333238-Choroidal Neovascularization,
pubmed-meshheading:17333238-Drug Therapy, Combination,
pubmed-meshheading:17333238-Feasibility Studies,
pubmed-meshheading:17333238-Female,
pubmed-meshheading:17333238-Fluorescein Angiography,
pubmed-meshheading:17333238-Humans,
pubmed-meshheading:17333238-Injections,
pubmed-meshheading:17333238-Macular Degeneration,
pubmed-meshheading:17333238-Male,
pubmed-meshheading:17333238-Photochemotherapy,
pubmed-meshheading:17333238-Photosensitizing Agents,
pubmed-meshheading:17333238-Porphyrins,
pubmed-meshheading:17333238-Prospective Studies,
pubmed-meshheading:17333238-Vascular Endothelial Growth Factor A,
pubmed-meshheading:17333238-Visual Acuity,
pubmed-meshheading:17333238-Vitreous Body
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
|
|
pubmed:affiliation |
U.D.A.T. Macular Imaging & Treatment Division, Hospital de Olhos de Araraquara, Rua Padre Duarte 989 apto 172, Araraquara, SP 14801-310, Brazil. roger.retina@globo.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
